These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 9199024)

  • 1. [Morphine metabolism--pharmacokinetics and pharmacodynamics].
    Andersen G; Christrup LL; Sjøgren P
    Ugeskr Laeger; 1997 May; 159(22):3383-6. PubMed ID: 9199024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is the reduced efficacy of morphine in diabetic rats caused by alterations of opiate receptors or of morphine pharmacokinetics?
    Courteix C; Bourget P; Caussade F; Bardin M; Coudore F; Fialip J; Eschalier A
    J Pharmacol Exp Ther; 1998 Apr; 285(1):63-70. PubMed ID: 9535995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of G(i)alpha2-protein in opioid tolerance and mu-opioid receptor downregulation in vivo.
    Yoburn BC; Gomes BA; Rajashekara V; Patel C; Patel M
    Synapse; 2003 Feb; 47(2):109-16. PubMed ID: 12454948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The competitive N-methyl-D-aspartate receptor antagonist (-)-6-phosphonomethyl-deca-hydroisoquinoline-3-carboxylic acid (LY235959) potentiates the antinociceptive effects of opioids that vary in efficacy at the mu-opioid receptor.
    Allen RM; Granger AL; Dykstra LA
    J Pharmacol Exp Ther; 2003 Nov; 307(2):785-92. PubMed ID: 12975489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mu-Opioid receptor internalization-dependent and -independent mechanisms of the development of tolerance to mu-opioid receptor agonists: Comparison between etorphine and morphine.
    Narita M; Suzuki M; Narita M; Niikura K; Nakamura A; Miyatake M; Yajima Y; Suzuki T
    Neuroscience; 2006; 138(2):609-19. PubMed ID: 16417975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Importance of sex and relative efficacy at the mu opioid receptor in the development of tolerance and cross-tolerance to the antinociceptive effects of opioids.
    Barrett AC; Cook CD; Terner JM; Craft RM; Picker MJ
    Psychopharmacology (Berl); 2001 Nov; 158(2):154-64. PubMed ID: 11702089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling.
    Wang HY; Friedman E; Olmstead MC; Burns LH
    Neuroscience; 2005; 135(1):247-61. PubMed ID: 16084657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morphine induces endocytosis of neuronal mu-opioid receptors through the sustained transfer of Galpha subunits to RGSZ2 proteins.
    Rodríguez-Muñoz M; de la Torre-Madrid E; Sánchez-Blázquez P; Garzón J
    Mol Pain; 2007 Jul; 3():19. PubMed ID: 17634133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Morphine-induced hyperalgesia, allodynia and myoclonus--new side-effects of morphine?].
    Jacobsen LS; Olsen AK; Sjøgren P; Jensen NH
    Ugeskr Laeger; 1995 Jun; 157(23):3307-10. PubMed ID: 7543228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the antinociceptive effect of acute morphine in female and male Sprague-Dawley rats using the long-lasting mu-antagonist methocinnamox.
    Peckham EM; Barkley LM; Divin MF; Cicero TJ; Traynor JR
    Brain Res; 2005 Oct; 1058(1-2):137-47. PubMed ID: 16139823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in tolerance to anti-hyperalgesic effects between chronic treatment with morphine and fentanyl under a state of pain.
    Imai S; Narita M; Hashimoto S; Nakamura A; Miyoshi K; Nozaki H; Hareyama N; Takagi T; Suzuki M; Narita M; Suzuki T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2006 Nov; 26(5-6):183-92. PubMed ID: 17240843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of TRPV1-expressing sensory neurons reduces spinal mu opioid receptors but paradoxically potentiates opioid analgesia.
    Chen SR; Pan HL
    J Neurophysiol; 2006 May; 95(5):3086-96. PubMed ID: 16467418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores.
    Lenard NR; Daniels DJ; Portoghese PS; Roerig SC
    Eur J Pharmacol; 2007 Jul; 566(1-3):75-82. PubMed ID: 17383633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How important is protein kinase C in mu-opioid receptor desensitization and morphine tolerance?
    Bailey CP; Smith FL; Kelly E; Dewey WL; Henderson G
    Trends Pharmacol Sci; 2006 Nov; 27(11):558-65. PubMed ID: 17000011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of cAMP-dependent protein kinase (PKA) in opioid agonist-induced mu-opioid receptor downregulation and tolerance in mice.
    Shen J; Benedict Gomes A; Gallagher A; Stafford K; Yoburn BC
    Synapse; 2000 Dec; 38(3):322-7. PubMed ID: 11020235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
    Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
    J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morphine hyperalgesia in mice is unrelated to opioid activity, analgesia, or tolerance: evidence for multiple diverse hyperalgesic systems.
    Juni A; Klein G; Kest B
    Brain Res; 2006 Jan; 1070(1):35-44. PubMed ID: 16409995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioids: cellular mechanisms of tolerance and physical dependence.
    Bailey CP; Connor M
    Curr Opin Pharmacol; 2005 Feb; 5(1):60-8. PubMed ID: 15661627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer-related bone pain is attenuated by a systemically available delta-opioid receptor agonist.
    Brainin-Mattos J; Smith ND; Malkmus S; Rew Y; Goodman M; Taulane J; Yaksh TL
    Pain; 2006 May; 122(1-2):174-81. PubMed ID: 16545911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.